1,074 results on '"Cervantes, F."'
Search Results
2. A new mouse of the Peromyscus maniculatus species complex (Cricetidae) from the highlands of central Mexico
3. Order-Fractal transition in abstract paintings
4. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
5. The Gravitational Universe
6. On-orbit alignment and diagnostics for the LISA Technology Package
7. A rural environment does not protect against asthma or other allergic diseases amongst Mexican children
8. The phylogenetic position of southern relictual species of Microtus (Muridae: Rodentia) in North America
9. Novel application of magnetic nano-carbon composite as redox mediator in the reductive biodegradation of iopromide in anaerobic continuous systems
10. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
11. Order-fractal transitions in abstract paintings
12. Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations
13. Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients
14. Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
15. High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists
16. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both
17. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia
18. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
19. P995: MYELOID NEOPLASMS-ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT
20. P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS
21. Abstract No. 379 Improving clinical outcome of necrotizing pancreatitis: retrospective review of through and through (U-tube) percutaneous drainage
22. P1026: COMPARATIVE GENOMIC PROFILING OF MYELOPROLIFERATIVE NEOPLASMS PRESENTING WITH AND WITHOUT SPLANCHNIC VEIN THROMBOSIS
23. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
24. A Framework to Assess Intelligent Decision-Making Support Systems
25. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
26. Concurrence of Anaerobic Ammonium Oxidation and Organotrophic Denitrification in Presence of p-Cresol
27. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
28. Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis
29. Repatriations to Guadalajara: An Experience of Collaboration between a Faith-based Organization and the Government
30. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
31. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview
32. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
33. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis
34. Ruxolitinib and survival improvement in patients with myelofibrosis
35. Spanish Sign Language Interpreter for Mexican Linguistics
36. Mutations and prognosis in primary myelofibrosis
37. Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea
38. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
39. IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis
40. Relación entre el día de colección y la recuperación de embriones en alpacas superovuladas
41. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
42. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders
43. Subtraction of test mass angular noise in the LISA technology package interferometer
44. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients
45. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group
46. Suspensión del tratamiento con inhibidores de BCR-ABL en los pacientes con leucemia mieloide crónica en respuesta molecular profunda dentro de la práctica clínica asistencial: Experiencia española en un total de 236 casos
47. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model: Prognostication in myelofibrosis
48. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution
49. Efecto del estadío del desarrollo folicular al momento de la monta sobre la ovulación y supervivencia embrionaria en alpacas
50. Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.